Immuneering Corp IMRX
We take great care to ensure that the data presented and summarized in this overview for Immuneering Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMRX
View all-
Cormorant Asset Management, LP Boston, MA3.3MShares$4.58 Million0.55% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.88MShares$2.62 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.38MShares$1.91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.2MShares$1.67 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD910KShares$1.27 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA463KShares$642,9020.0% of portfolio
-
Goldman Sachs Group Inc New York, NY454KShares$631,3830.0% of portfolio
-
State Street Corp Boston, MA377KShares$523,8850.0% of portfolio
-
High Vista Strategies LLC Boston, MA255KShares$353,7730.29% of portfolio
-
Northern Trust Corp Chicago, IL176KShares$244,6460.0% of portfolio
Latest Institutional Activity in IMRX
Top Purchases
Top Sells
About IMRX
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Insider Transactions at IMRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2024
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
400,000
-1.52%
|
$1,200,000
$3.01 P/Share
|
|
Mar 22
2024
|
Thomas J. Schall Director |
BUY
Open market or private purchase
|
Direct |
2,900
+50.0%
|
$5,800
$2.55 P/Share
|
|
Mar 22
2024
|
Harold Eugene Brakewood Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
3,900
+50.0%
|
$7,800
$2.57 P/Share
|
|
Mar 22
2024
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
25,000
+18.28%
|
$50,000
$2.55 P/Share
|
|
Mar 22
2024
|
Mallory Morales Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
393
+4.53%
|
$786
$2.55 P/Share
|
|
Mar 21
2024
|
Mallory Morales Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
1,107
+12.31%
|
$2,214
$2.72 P/Share
|
|
Mar 20
2024
|
Leah R Neufeld CHIEF PEOPLE OFFICER |
BUY
Open market or private purchase
|
Direct |
3,818
+27.57%
|
$7,636
$2.88 P/Share
|
|
Mar 20
2024
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
7,000
+1.98%
|
$14,000
$2.86 P/Share
|
|
Mar 19
2024
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
25,000
+22.37%
|
$50,000
$2.56 P/Share
|
|
Mar 19
2024
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+0.87%
|
$40,000
$2.77 P/Share
|
|
Mar 18
2024
|
Ann E Berman Director |
BUY
Open market or private purchase
|
Direct |
57,965
+46.21%
|
$115,930
$2.13 P/Share
|
|
Mar 18
2024
|
Peter Feinberg Director |
BUY
Open market or private purchase
|
Direct |
50,000
+25.84%
|
$100,000
$2.68 P/Share
|
|
Mar 15
2024
|
Mallory Morales Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,344
+39.06%
|
$4,344
$1.62 P/Share
|
|
Mar 15
2024
|
Leah R Neufeld CHIEF PEOPLE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+50.0%
|
$6,211
$1.62 P/Share
|
|
Mar 15
2024
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+1.8%
|
$6,211
$1.62 P/Share
|
|
Mar 15
2024
|
Michael Bookman CHIEF LEGAL OFFICER, SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
1,448
+27.33%
|
$1,448
$1.62 P/Share
|
|
Mar 15
2024
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
400,000
-10.82%
|
$800,000
$2.14 P/Share
|
|
Mar 14
2024
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
509,091
-3.13%
|
$2,036,364
$4.71 P/Share
|
|
Dec 22
2022
|
Benjamin J. Zeskind PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.11%
|
$7,500
$3.01 P/Share
|
|
May 25
2022
|
Brett Matthew Hall CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
2,551
+0.76%
|
$7,653
$3.92 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 197K shares |
|---|---|
| Grant, award, or other acquisition | 18.2K shares |
| Open market or private sale | 1.31M shares |
|---|